Ascentage Pharma Group International 6-K, filed Aug 13, 2026
Ascentage Pharma Group International (AAPG)
About this 6-K
Ascentage Pharma Group International filed this 6-K on August 13, 2026.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of August 2026
Commission File Number: 001-42484
ASCENTAGE PHARMA GROUP INTERNATIONAL
(Translation of Registrant’s name into English)
68 Xinqing Road
Suzhou Industrial Park
Suzhou, Jiangsu
China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On August 5, 2026, Ascentage Pharma Group International (“Ascentage Pharma” or the “Company”) issued a press release entitled, “CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026”. A copy of the press release is furnished as Exhibit 99.1 to this Report. On August 13, 2026, Ascentage Pharma Group International issued an English language and Chinese language version of a press release entitled, “Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit”. Copies of the press releases are furnished as Exhibits 99.2 and 99.3 to this Report.
1
INDEX TO EXHIBITS
| Exhibit Number | Exhibit Title | |
|
99.1 |
||
| 99.2 | EN Press release dated August 13, 2026 | |
| 99.3 | CN Press release dated August 13, 2026 |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ASCENTAGE PHARMA GROUP INTERNATIONAL | ||
| Date: August 13, 2026 | /s/ Dajun Yang | |
| Name: | Dajun Yang | |
| Title: | Chief Executive Officer | |
3
Exhibit 99.1
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
In a release issued under the same headline earlier today by Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855),
please note that in the first paragraph of the release, the time should be 7:00 am Eastern Daylight Time (EDT) on August 19, 2026 / 7:00 pm Hong Kong Time (HKT) and not 9 am EDT and 9 pm HKT as previously stated.
The corrected release follows:
ROCKVILLE, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that it will release its six months 2026 unaudited interim results and provide business updates at 7:00 am Eastern Daylight Time (EDT) on August 19, 2026 / 7:00 pm Hong Kong Time (HKT) on August 19, 2026.
Analysts and investors are invited to join the investor webcast with Q&A, conducted by the Company’s management team.
Ascentage Pharma will host a Chinese (Mandarin) language investor webcast at 9:00 pm EDT on August 19, 2026 / 9:00 am HKT on August 20, 2026. To access the Chinese language investor event or conference call, please register in advance here.
The English language investor conference call and webcast will be held at 8:00 am EDT / 8:00 pm HKT on August 20, 2026. To access the English language webcast, please register in advance here. The webcast replay for the English language conference call and presentation will also be available on the News & Events page of the Ascentage Pharma website.
About Ascentage Pharma
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.
The Company’s first approved product, Olverembatinib, is the first novel third- generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA- and EMA-cleared registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as an FDA- and EMA-cleared registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.
The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA- and EMA- cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA- and EMA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS.
Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 29, 2026, the sections headed “Forward-looking Statements” and “Risks Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited where the Company’s ordinary shares are listed it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.
As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information:
Stella Yang
Ascentage Pharma
IR@ascentage.com
+1 (301) 792-6286
Exhibit 99.2
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
ROCKVILLE, MD, August 13, 2026 -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management will participate in the Evercore ISI 2nd Annual China Biotech Summit, being held August 17-19, 2026 at The Ritz-Carlton Shanghai, Pudong.
Management will participate in a fireside chat moderated by the Evercore research team and one-on-one investor meetings during the conference.
Fireside Chat
Date: August 18, 2026
Time: 7:45-8:00am Beijing Time
Location: The Ritz-Carlton Shanghai, Pudong, Grand Ballroom 2 & 3
Investors interested in scheduling a meeting with the Ascentage Pharma management team should contact their Evercore representative.
About Ascentage Pharma
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.
The Company’s first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA- and EMA-cleared registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as FDA- and EMA-cleared registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.
The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA- and EMA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA- and EMA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS.
Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 29, 2026, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited where the Company’s ordinary shares are listed it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this press release do not constitute profit forecast by the Company’s management.
2
As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information
Investor Relations:
Sumedh Sunkaraneni
Ascentage Pharma
IR@ascentage.com
+1 (301) 792-6286
Brian Korb
astr partners
brian.korb@astrpartners.com
+1 (917) 653-5122
3
Exhibit 99.3
亚盛医药受邀出席Evercore第二届中国生物科技峰会并参加炉边谈话
中国苏州，2026年8月13日–致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药（纳斯达克代码：AAPG；香港联交所代码：6855）今日宣布，公司管理层将出席于2026年8月17日-19日在上海浦东丽思卡尔顿酒店举办的Evercore第二届中国生物科技峰会。
会议期间，公司管理层将参与由Evercore研究团队主持的炉边谈话，并开展一对一投资者交流会。
炉边谈话
日期：2026年8月18日
时间：北京时间上午7:45–8:00
地点：上海浦东丽思卡尔顿酒店，大宴会厅2厅和3厅
尊敬的投资人，如您有意与亚盛医药管理层会面交流，请联系您对应的Evercore客户代表。
关于亚盛医药
亚盛医药（纳斯达克代码：AAPG；香港联交所代码：6855）是一家综合性的全球生物医药企业，致力于研发、生产和商业化创新药，以解决肿瘤领域全球患者尚未满足的临床需求。公司已建立丰富的创新药产品管线，包括抑制Bcl-2和 MDM2-p53 等细胞凋亡通路关键蛋白的抑制剂、新一代针对癌症治疗中出现的激酶突变体的抑制剂以及蛋白降解剂。
公司核心品种耐立克®是中国首个获批上市的第三代BCR-ABL抑制剂，已获批用于治疗伴有T315I突变的慢性髓细胞白血病慢性期（CML-CP）和加速期（CML-AP）患者，以及对一代和二代TKI耐药和/或不耐受的CML-CP成年患者。该药物所有获批适应症均已被纳入中国国家医保药品目录（NRDL）。目前，亚盛医药正在开展耐立克®三项全球注册III期临床研究，分别为：获美国FDA和欧洲EMA许可的评估耐立克®治疗新诊断费城染色体阳性急性淋巴细胞白血病（Ph+ ALL）患者POLARIS-1研究；获美国FDA和欧洲EMA许可的评估耐立克®治疗经治CML-CP成年患者的POLARIS-2研究；评估耐立克®治疗SDH-缺陷型GIST患者的POLARIS-3研究。
公司另一重磅品种利生妥®是一款用于治疗多种血液系统恶性肿瘤的新型Bcl-2抑制剂。利生妥®已获中国国家药品监督管理局（NMPA）批准，用于治疗既往至少接受过一种包括布鲁顿酪氨酸激酶（BTK）抑制剂在内的系统治疗的成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者。目前，亚盛医药正在开展利生妥®四项全球注册III期临床研究，分别为：获美国FDA和欧洲EMA许可的评估利生妥®联合BTK抑制剂治疗既往接受BTK抑制剂治疗超过12个月且应答不佳的CLL/SLL患者的GLORA研究；评估利生妥®一线治疗初治CLL/SLL患者的GLORA-2研究；评估利生妥®一线治疗新诊断老年或不耐受的AML患者的GLORA-3研究；以及获美国FDA和欧洲EMA许可的评估利生妥®一线治疗新诊断中高危 MDS患者的GLORA-4研究。
2
凭借强大的研发能力，亚盛医药已在全球范围内进行知识产权布局，并与武田、阿斯利康、默沙东、辉瑞、信达等众多领先的生物制药公司达成全球合作，同时与丹娜法伯癌症研究院、梅奥医学中心、美国国家癌症研究所和密西根大学等学术机构建立研发合作关系。如需了解更多信息，请访问 https://ascentage.com/
前瞻性声明
本新闻稿包含根据美国《1995年私人证券诉讼改革法案》，以及经修订的《1933年证券法》第27A条和《1934年证券交易法》第21E条所界定的前瞻性陈述。除历史事实陈述外，本新闻稿中的所有内容均可能构成前瞻性陈述，包括亚盛医药对未来事件、经营成果或财务状况所发表的意见、预期、信念、计划、目标、假设或预测。
这些前瞻性陈述受到诸多风险和不确定性的影响，具体内容已在亚盛医药向美国证券交易委员会（SEC）提交的文件中详细说明，包括2026年4月29日提交的20-F表格中截止2025年12月31日的年度报告中的”风险因素”和”关于前瞻性声明的警示声明”章节，2019年10月16日提交的首次发行上市招股书中的“前瞻性声明”、“风险因素”章节，以及我们不时向SEC或HKEX提交的其他文件。这些因素可能导致实际业绩、运营水平、经营成果或成就与前瞻性陈述中明示或暗示的信息存在重大差异。本前瞻性声明中的陈述不构成公司管理层的利润预测。
因此，该等前瞻性陈述不应被视为对未来事件的预测。本新闻稿中的前瞻性陈述仅基于亚盛医药当前对未来发展及其潜在影响的预期和判断，且仅代表截至陈述发表之日的观点。无论出现新信息、未来事件或其他情况，亚盛医药均无义务更新或修订任何前瞻性陈述。
3